TIRZEPATIDE · 60 MG/3 ML (20 MG/ML) · VIAL MULTIDOSIS - Agonista Dual GIP/GLP-1

Key Benefits of Tirzepatide Dual GIP/GLP-1 Agonist for Advanced Research Tirzepatide is a synthetic research peptide that acts as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual activation provides a synergistic effect that potentiates glycemic control and promotes weight reduction. Synergistic Incretin Receptor Activation Tirzepatide binds and simultaneously activates both GIP and GLP-1 receptors, which are key in regulating glucose homeostasis. GLP-1 activation stimulates insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite. GIP, in turn, potentiates insulin secretion, improves insulin sensitivity in adipose tissue and skeletal muscle, and reduces ectopic fat accumulation. The combination of both agonists provides an additive and synergistic effect that surpasses single receptor agonists. Advanced Metabolic Research Tirzepatide enables the study of dual agonist mechanisms in glucose metabolism, appetite regulation, and body composition. Its efficacy in weight reduction and glycemic control has been demonstrated in clinical trials, with weight reductions of up to 19.7% over 176 weeks and a risk reduction of progression to type 2 diabetes of up to 93%. Cardiovascular and Renal Research Applications Emerging evidence suggests that tirzepatide may confer cardiovascular and chronic kidney disease benefits. Research studies are exploring these effects through mechanisms involving improved endothelial function, reduced inflammation, and blood pressure modulation. Longevity and Neuroprotection Research Emerging evidence suggests that GLP-1 agonists may have neuroprotective and mental health effects. Incretin pathway modulation has been shown to influence cellular signaling related to aging and tissue regeneration in animal models. High Purity and Pharmaceutical Quality Research-grade peptide with ≥98% purity. Formulation in a 3 mL multi-dose vial with 20 mg/mL concentration (60 mg total). Recommended storage between 2°C and 8°C. Protect from light. Do not freeze. For Research Use Only Product intended exclusively for research (Research Use Only). Not approved for human or veterinary use.

Function and Mechanism of Action of Tirzepatide Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Its chemical name is Tirzepatide and its CAS number is 2023788-19-2. Its sequence includes two non-natural aminoisobutyric acid (Aib) residues at positions 2 and 13, which confer resistance to proteolytic degradation and an extended half-life. Detailed Mechanism of Action: Molecular Structure: Tirzepatide is a 39-amino acid peptide with a molecular weight of approximately 4813 g/mol and molecular formula C₂₂₅H₃₄₈N₄₈O₆₈. Its sequence includes two non-natural aminoisobutyric acid (Aib) residues that confer resistance to proteolytic degradation, extending its half-life and enabling weekly dosing in studies. The peptide possesses a modification at residue Lys20 with a C20 fatty acid side chain that improves serum albumin binding and prolongs its action. GLP-1 Receptor Activation: Tirzepatide binds to the GLP-1 receptor with high affinity, activating the cAMP signaling pathway. This stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, delays gastric emptying, and reduces appetite through central effects. GLP-1 receptor activation has also demonstrated cardioprotective, neuroprotective, and anti-inflammatory effects in research studies. GIP Receptor Activation: Tirzepatide also binds to the GIP receptor, activating additional signaling pathways. GIP potentiates glucose-dependent insulin secretion, improves insulin sensitivity in adipose tissue and skeletal muscle, promotes lipid storage in white adipose tissue, and reduces ectopic fat accumulation in muscle. GIP also has effects on appetite and satiety, although the precise mechanisms are still being investigated. GIP/GLP-1 Synergy: Simultaneous activation of both receptors produces a synergistic effect that potentiates glycemic control and promotes greater weight reduction compared to single receptor agonists. GIP potentiates GLP-1 effects, leading to tirzepatide being proposed as a &amp;amp;amp;quot;super-GLP-1&amp;amp;amp;quot;. Evidence suggests that GIP may potentiate GLP-1&amp;amp;amp;#039;s anorectic effects and improve insulin sensitivity. Route of Administration and Research: Tirzepatide is administered subcutaneously in research studies. The 3 mL multi-dose vial with 20 mg/mL concentration facilitates dosing under multiple experimental conditions. Storage: Preferably store between 2°C and 8°C (refrigeration). Do not freeze. Protect from light. Research Quality: Research-grade peptide with ≥98% purity. Manufactured under strict quality control standards. Research Use Only.

How to Use Tirzepatide Route of Administration: Subcutaneous (for research). Tirzepatide is administered subcutaneously in research studies. For research use only by qualified personnel in laboratory settings. Dosage: Dosage should be determined according to the specific research protocol and experimental conditions. General dosage guidelines for tirzepatide in research include: Research Ranges: Research studies have used weekly doses that vary according to the experimental model and study objectives. Frequency: Weekly administration in research studies, due to the peptide&amp;amp;amp;#039;s extended half-life. Treatment Duration: Treatment duration in research studies varies according to experimental design, from acute studies to long-term studies of 72-176 weeks. Storage: Preferably store between 2°C and 8°C (refrigeration). Do not freeze. Protect from light. Keep out of reach of children. Multi-Dose Vial Instructions: This product is a multi-dose vial designed to contain more than one research dose. It is recommended to: - Use the vial only in a clean, designated area for injection preparation. - Clean the vial stopper with an alcohol pad before each use. - Use new sterile needles and syringes for each withdrawal. - Label the vial with the opening date and time. - Discard the vial within 28 days of opening, unless the manufacturer specifies a different period. - Never combine partial doses from multiple vials. Important Notice: Product intended FOR RESEARCH USE ONLY. Not approved for human use, diagnosis, treatment, or prevention of disease. Do not exceed the doses specified in the research protocol. Consult with a principal investigator or ethics committee before starting any research.

Ingredients of Tirzepatide Composition per mL: Active Ingredient: Tirzepatide: 20 mg CAS Number: 2023788-19-2 Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈ Molecular Weight: ~4813 g/mol Sequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ Vehicle: Water for Injection: Sterile vehicle for the formulation. Excipients: The formulation may contain additional excipients such as buffering agents, preservatives, and stabilizers to ensure peptide integrity and formulation stability (consult the product leaflet for the complete list of ingredients). Note for Users: This product is a research-grade peptide manufactured under strict quality control standards. Each vial contains 3 mL of solution, with a concentration of 20 mg/mL (60 mg total). Preferably store between 2°C and 8°C. Do not freeze. Protect from light. Research Use Only.

Onset Time &amp;amp;amp;amp; Expected Results of Tirzepatide Onset of Action (Hours to Days): In research studies, tirzepatide begins to exert its effects within the first hours after subcutaneous administration. Activation of GLP-1 and GIP receptors stimulates insulin secretion and suppresses glucagon in response to nutrient intake. Effects on appetite and satiety can be observed within the first days. Measurable Benefits (Weeks 4-8): The first measurable changes in body weight, glycemic control, and metabolic markers begin to be visible within the first 4-8 weeks of administration in research studies. Studies have demonstrated significant weight reductions in this period. Full Effect (Weeks 12-24): For maximum benefit in weight reduction, glycemic control, and metabolic effects, the full effect often requires 12-24 weeks of administration in research studies. Clinical trials have demonstrated weight reductions of up to 19.7% over 176 weeks. Projected Results (Research Studies): - Significant weight reduction: Decrease in body weight in study models - Improved glycemic control: Reduction in blood glucose levels - Improved insulin sensitivity: Greater efficiency in glucose utilization - Appetite reduction: Decrease in caloric intake in study models - Improved metabolic markers: Reduction in inflammation and improved lipid profile Factors Influencing Results: The speed and magnitude of results depend on dose administered, adherence to the research protocol, experimental conditions, study model, individual metabolism, and genetics.

Clinical Research &amp;amp;amp;amp; 3rd Party Test Results of Tirzepatide Scientific evidence on tirzepatide comes from clinical trials and research studies in metabolism, endocrinology, and cellular biology. Clinical Evidence in Humans: SURMOUNT-1 Trial: The SURMOUNT-1 trial demonstrated that tirzepatide produced weight reduction of up to 19.7% over 176 weeks in adults with obesity or overweight. The study also demonstrated a risk reduction of progression to type 2 diabetes of up to 93%. SURPASS Trials: The SURPASS trials have demonstrated the efficacy of tirzepatide in glycemic control in patients with type 2 diabetes, with significant reductions in HbA1c and body weight. Research Studies: Emerging evidence suggests that tirzepatide may confer benefits in cardiovascular diseases, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease. Safety Considerations: Side Effects in Research: In clinical studies, the most common side effects have been gastrointestinal (nausea, vomiting, diarrhea), generally mild to moderate and transient. Contraindications: Research product. Not approved for human use. Not recommended for individuals with a history of pancreatitis, severe kidney disease, or hypersensitivity to the compound. Regulatory Status: Tirzepatide is approved for clinical use in some countries for the treatment of type 2 diabetes and obesity. This product is research-grade and is not intended for human use. Quality Standards of Kinetix Smartpharma: Research Grade: Research-grade peptide with ≥98% purity. Manufacturing: Manufactured under strict quality control standards (GMP). Quality Control: Each batch is subjected to quality control testing to ensure purity, potency, and sterility. Note: This product is a research compound and is not intended for human use, diagnosis, treatment, or prevention of disease. Results may vary according to the study model and experimental conditions.

Product Details

TIRZEPATIDE · 60 MG/3 ML (20 MG/ML) · VIAL MULTIDOSIS - Agonista Dual GIP/GLP-1

TIRZEPATIDE · 60 MG/3 ML (20 MG/ML) · VIAL MULTIDOSIS - Agonista Dual GIP/GLP-1

Build Your Stack

Frequently Asked Questions